Development of an inactivated vaccine candidate for SARS-CoV-2-Reference-Cited by-同舟云学术

Development of an inactivated vaccine candidate for SARS-CoV-2

Published:2020-07-03 Issue:6499 Volume:369 Page:77-81
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Gao Qiang¹^ORCID,Bao Linlin²^ORCID,Mao Haiyan³^ORCID,Wang Lin¹^ORCID,Xu Kangwei⁴^ORCID,Yang Minnan⁵^ORCID,Li Yajing¹^ORCID,Zhu Ling⁵^ORCID,Wang Nan⁵^ORCID,Lv Zhe⁵^ORCID,Gao Hong²^ORCID,Ge Xiaoqin¹^ORCID,Kan Biao⁶^ORCID,Hu Yaling¹^ORCID,Liu Jiangning²^ORCID,Cai Fang¹^ORCID,Jiang Deyu¹^ORCID,Yin Yanhui¹^ORCID,Qin Chengfeng⁷^ORCID,Li Jing¹^ORCID,Gong Xuejie¹^ORCID,Lou Xiuyu³^ORCID,Shi Wen³^ORCID,Wu Dongdong¹^ORCID,Zhang Hengming¹^ORCID,Zhu Lang¹^ORCID,Deng Wei²^ORCID,Li Yurong¹^ORCID,Lu Jinxing⁶^ORCID,Li Changgui⁴^ORCID,Wang Xiangxi⁵^ORCID,Yin Weidong¹^ORCID,Zhang Yanjun³^ORCID,Qin Chuan²^ORCID

Affiliation:

1. Sinovac Biotech Ltd., Beijing, China.

2. Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.

3. Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.

4. Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China.

5. CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

6. National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China.

7. Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.

Abstract

Vaccine candidate tested in monkeys Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race to develop a vaccine. Gao et al. report preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies. The researchers obtained multiple SARS-CoV-2 strains from 11 hospitalized patients across the world and then chemically inactivated the harmful properties of the virus. Animals were immunized with one of two vaccine doses and then inoculated with SARS-CoV-2. Those that received the lowest dose showed signs of controlling the infection, and those receiving the highest dose appeared more protected and did not have detectable viral loads in the pharynx or lungs at 7 days after infection. The next steps will be testing for safety and efficacy in humans. Science , this issue p. 77

Funder

National Key Research and Development Program

Ten Thousand Talent Program and the NSFS Innovative Research Group

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference23 articles.

1. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

2. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

3. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

4. Developing Covid-19 Vaccines at Pandemic Speed

5. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Cited by 1146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and limitations of repurposed drugs and vaccines for COVID-19;Journal of Medicine, Surgery, and Public Health;2024-04

2. Comparative Review of the State of the Art in Research on the Porcine Epidemic Diarrhea Virus and SARS-CoV-2, Scope of Knowledge between Coronaviruses;Viruses;2024-02-02

3. The Long-Term Serological Profile of CoronaVac Vaccine Based on Comorbidities and History of SARS-CoV-2 Infection in Indonesia;Japanese Journal of Infectious Diseases;2024-01-31

4. Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through multiple mechanisms;2024-01-30

5. Evaluation of SARS-CoV-2 Antibody Levels in Pharmacists and Pharmacy Staff Following CoronaVac Vaccination;Turkish Journal of Pharmaceutical Sciences;2024-01-19